| Pathological heterogeneity | Different underlying pathologies show varying degrees of cerebellar involvement |
| Disease stage | Ataxic features may emerge or worsen as the disease progresses |
| Assessment methodology | Subtle ataxia may be missed without specialized examination |
| CBS subtype | Certain clinical variants show higher rates of ataxia |
| Purkinje cell degeneration | Loss of Purkinje cells in the cerebellar cortex is a recognized feature in some CBS cases[@cbsneuro2023] |
| Cerebellar nuclear involvement | Degeneration of deep cerebellar nuclei (dentate, globose, emboliform) |
| White matter tract damage | Disruption of cerebellar peduncles connecting the cerebellum to cortical and subcortical structures |
| Tau pathology | 4R tau deposition in cerebellar neurons and processes |
| Brainstem involvement | Cerebellar ataxia can result from brainstem lesions affecting cerebellar afferents/efferents |
| Thalamic dysfunction | The cerebellum connects to the thalamus, which can be affected in CBS |
| Cortical-cerebellar disconnection | Damage to frontal-parietal regions disrupts cerebellar modulation |
| Drug-induced ataxia | Medications used for CBS symptoms (e.g., benzodiazepines, anticonvulsants) can cause or worsen ataxia |
| Databases | OMIMOrphanetClinicalTrialsPubMed |